Calcified Tissue International

, Volume 79, Issue 2, pp 69–75 | Cite as

Methotrexate, Azathioprine, Cyclosporine, and Risk of Fracture

Article

Abstract

We studied the fracture risk associated with use of methotrexate, azathioprine, and cyclosporine. The study was designed as a case-control study. All patients with a fracture (n = 124,655) in the year 2000 in Denmark served as cases. Information on fractures and confounders was retrieved from the National Hospital Discharge Register and a number of other national registers. For each case, three age- and gender-matched controls were randomly drawn from the general population (n = 373,962). Exposure was use of the drugs and a number of covariates including other immunosuppressive drugs, corticosteroids, any cancer, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, liver and kidney disease, prior fracture, and alcoholism. Azathioprine was associated with an increase in overall fracture risk, but besides this, none of the drugs was significantly associated with overall fracture risk or risk of hip, spine, or forearm fracture. Liver [odds ratio (OR) = 1.55, 95% confidence interval (CI) 1.42–1.69] and kidney (OR = 1.26, 95% CI 1.16–1.37) diseases were significantly associated with increased risk of fractures. Azathioprine was associated with an increase in overall fracture risk but not in the risk of spine, hip, or forearm fractures. Methotrexate and cyclosporine were not associated with fracture risk. It thus seems that the underlying disease for which the treatment is administered may be responsible for much of the increase in fracture risk rather than the drugs used to treat the disorder in question.

Keywords

Methotrexate Azathioprine Cyclosporine Fracture risk 

References

  1. 1.
    Salmon SE (1987) Drugs and the immune system. In: Katzung BG (ed), Basic and Clinical Pharmacology. Appleton & Lange, East Norwalk, CT, pp 702–718Google Scholar
  2. 2.
    Ferraccioli GF, Di Poi E, Damato R (2000) Steroid sparing therapeutic approaches to polymyalgia rheumatica-giant cell arteritis. State of the art and perspectives. Clin Exp Rheumatol 18:S58–S60PubMedGoogle Scholar
  3. 3.
    Ferraccioli G, Salaffi F, De Vita S, et al. (1996) Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 23:624–628PubMedGoogle Scholar
  4. 4.
    Davies H, Olson L, Gibson P (2000) Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev CD000391Google Scholar
  5. 5.
    Lewis SJ, Ainslie GM, Bateman ED (1999) Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16:87–92PubMedGoogle Scholar
  6. 6.
    Vestergaard P, Rejnmark L, Mosekilde L (2005) Fracture risk associated with systemic and topical corticosteroids. J Intern Med 257:374–384PubMedCrossRefGoogle Scholar
  7. 7.
    van Staa TP, Leufkens HGM, Abenhaim L, et al. (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRefGoogle Scholar
  8. 8.
    van Staa TP, Leufkens HGM, Cooper C (2001) Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 16:581–588PubMedCrossRefGoogle Scholar
  9. 9.
    van Staa TP, Laan RF, Barton IP, et al. (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229PubMedCrossRefGoogle Scholar
  10. 10.
    Herrala J, Puolijoki H, Impivaara O, et al. (1994) Bone mineral density in asthmatic women on high dose inhaled beclomethasone dipropionate. Bone 15:621–623PubMedCrossRefGoogle Scholar
  11. 11.
    Laan RF, van Riel PL, van de Putte LB, et al. (1993) Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomised controlled study. Ann Intern Med 119:963–968PubMedGoogle Scholar
  12. 12.
    Wong CA, Walsh LJ, Smith CJ, et al. (2000) Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 355:1399–1403PubMedCrossRefGoogle Scholar
  13. 13.
    Spiera RF, Mitnick HJ, Kupersmith M, et al. (2001) A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19:495–501PubMedGoogle Scholar
  14. 14.
    van Staa TP, Bishop N, Leufkens HG, et al. (2004) Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporosis Int 15:785–791CrossRefGoogle Scholar
  15. 15.
    Pfeilschifter J, Diel IJ (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570–1593PubMedGoogle Scholar
  16. 16.
    van der Sluis I, van den Heuvel-Eibrink MM, Hahlen K, et al. (2000) Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. Med Pediatr Oncol 35:415–420PubMedCrossRefGoogle Scholar
  17. 17.
    Friedlaender GE, Tross RB, Doganis AC, et al. (1984) Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (Adriamycin) treatment in a rat model. J Bone Joint Surg Am 66:602–607PubMedGoogle Scholar
  18. 18.
    Pelker RR, Friedlaender GE, Panjabi MM, et al. (1985) Chemotherapy-induced alterations in the biomechanics of rat bone. J Orthop Res 3:91–95PubMedCrossRefGoogle Scholar
  19. 19.
    Gnudi S, Butturini L, Ripamonti C, et al. (1988) The effects of methotrexate (MTX) on bone. A densitometric study conducted on 59 patients with MTX administered at different doses. Ital J Orthop Traumatol 14:227–231PubMedGoogle Scholar
  20. 20.
    Buckley LM, Leib ES, Cartularo KS, et al. (1997) Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 24:1489–1494PubMedGoogle Scholar
  21. 21.
    Carbone LD, Kaeley G, McKown KM, et al. (1999) Effects of long-term administration of methotrexate on bone mineral density in rheumatoid arthritis. Calcif Tissue Int 64:100–101PubMedCrossRefGoogle Scholar
  22. 22.
    Cranney AB, McKendry RJ, Wells GA, et al. (2001) The effect of low dose methotrexate on bone density. J Rheumatol 28:2395–2399PubMedGoogle Scholar
  23. 23.
    Di Munno O, Mazzantini M, Sinigaglia L, et al. (2004) Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol 31:1305–1309PubMedGoogle Scholar
  24. 24.
    Mazzantini M, Di Munno O, Incerti-Vecchi L, et al. (2000) Vertebral bone mineral density changes in female rheumatoid arthritis patients treated with low-dose methotrexate. Clin Exp Rheumatol 18:327–331PubMedGoogle Scholar
  25. 25.
    Minaur NJ, Kounali D, Vedi S, et al. (2002) Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford) 41:741–749CrossRefGoogle Scholar
  26. 26.
    Tascioglu F, Oner C, Armagan O (2003) The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis. Rheumatol Int 23:231–235PubMedCrossRefGoogle Scholar
  27. 27.
    Ragab AH, Frech RS, Vietti TJ (1970) Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer 25:580–585PubMedCrossRefGoogle Scholar
  28. 28.
    Stanisavljevic S, Babcock AL (1977) Fractures in children treated with methotrexate for leukemia. Clin Orthop Relat Res 125:139–144PubMedGoogle Scholar
  29. 29.
    Maenpaa HM, Soini I, Lehto MU, et al. (2002) Insufficiency fractures in patients with chronic inflammatory joint diseases. Clin Exp Rheumatol 20:77–79PubMedGoogle Scholar
  30. 30.
    Ferraccioli G, Casatta L, Bartoli E (1996) Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy. J Rheumatol 23:1539–1542PubMedGoogle Scholar
  31. 31.
    Aris RM, Neuringer IP, Weiner MA, et al. (1996) Severe osteoporosis before and after lung transplantation. Chest 109:1176–1183PubMedGoogle Scholar
  32. 32.
    Wacholder S, McLaughlin JK, Silverman DT, et al. (1992) Selection of controls in case-control studies. I. Principles. Am J Epidemiol 135:1019–1028PubMedGoogle Scholar
  33. 33.
    Vestergaard P, Emborg C, Støving RK, et al. (2002) Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders - a nation-wide register study. Int J Eat Disord 32:301–308PubMedCrossRefGoogle Scholar
  34. 34.
    Vestergaard P, Rejnmark L, Mosekilde L (2004) Fracture risk associated with use of anti-epileptic drugs. Epilepsia 45:1330–1337PubMedCrossRefGoogle Scholar
  35. 35.
    Rejnmark L, Vestergaard P, Mosekilde L (2005) Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int 76:167–175PubMedCrossRefGoogle Scholar
  36. 36.
    Rejnmark L, Vestergaard P, Mosekilde L (2006) Fracture risk in patients treated with loop diuretics. J Intern Med 259:117–124PubMedCrossRefGoogle Scholar
  37. 37.
    Klotzbuecher CM, Ross PD, Landsman PB, et al. (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739PubMedCrossRefGoogle Scholar
  38. 38.
    Kanis JA, Johansson H, Johnell O, et al. (2005) Alcohol intake as a risk factor for fracture. Osteoporosis Int 16:737–742CrossRefGoogle Scholar
  39. 39.
    Andersen TF, Madsen M, Jørgensen J, et al. (1999) The Danish National Hospital Register. Dan Med Bull 46:263–268PubMedGoogle Scholar
  40. 40.
    Munk-Jørgensen P, Mortensen PB (1997) The Danish Psychiatric Central Register. Dan Med Bull 44:82–84PubMedGoogle Scholar
  41. 41.
    Mosbech J, Jørgensen J, Madsen M, et al. (1995) The Danish National Patient Register: evaluation of data quality [in Danish]. Ugeskr Læger 157:3741–3745PubMedGoogle Scholar
  42. 42.
    Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nation-wide follow-up study in 16,416 patients in Denmark. Am J Epidemiol 156:1–10PubMedCrossRefGoogle Scholar
  43. 43.
    Zonneveld IM, Bakker WK, Dijkstra PF, et al. (1996) Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 132:184–187PubMedCrossRefGoogle Scholar
  44. 44.
    Van Leeuwen BL, Kamps WA, Jansen HW, et al. (2000) The effect of chemotherapy on the growing skeleton. Cancer Treat Rev 26:363–376PubMedCrossRefGoogle Scholar
  45. 45.
    Van Leeuwen BL, Verkerke GJ, Hartel RM, et al. (2003) Chemotherapy decreases epiphyseal strength and increases bone fracture risk. Clin Orthop Relat Res 413:243–254PubMedCrossRefGoogle Scholar
  46. 46.
    Hoidrup S, Grønbæk M, Gottschau A, et al. (1999) Alcohol intake, beverage preference, and risk of hip fracture in men and women. Am J Epidemiol 149:993–1001PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Department of Endocrinology and Metabolism CAarhus Amtssygehus, Aarhus University HospitalAarhus CDenmark

Personalised recommendations